Status:
COMPLETED
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
Lead Sponsor:
University Health Network, Toronto
Conditions:
Metastatic, Stage III or Stage IV, Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a phase II clinical study for patients with metastatic (the cancer has spread to other parts of the body) melanoma. Patients will receive an infusion (given by vein) of autologous tumor infilt...
Eligibility Criteria
Inclusion
- Inclusion Criteria (Eligibility for TIL Evaluation):
- Must have measurable, unresectable stage III or stage IV melanoma
- Suitable tumor for collection
- If tumor is suitable for collection, patient must be suitable for surgery
- Patient must be 18 years of age or older
- Performance status of ECOG 0 or 1
- Life expectancy \> 5 months from date of consent of TIL evaluation
- Willing to be tested for transmissible diseases
- For patients with a history of allergy to penicillin, gentamycin, streptomycin, or anti-fungals, the ability to generate TILs will be confirmed with the cell manufacturing laboratory
- Inclusion Criteria (Eligibility for Treatment):
- Signed and dated the informed consent
- No brain metastases or stable brain metastases for 3 months following definitive treatment.
- Life expectancy \> 3 months from the date of consent for TILs treatment
- TILs are suitable for use as determined by laboratory
- More than 30 days since any prior systemic therapy at the time of the cell infusion, or more than six weeks since prior nitrosurea therapy. For patients with prior ipilimumab therapy, at least six weeks must elapse between the last ipilimumab dose and the start of study treatment. All side effects from previous treatment must have recovered to an acceptable grade level.
- Adequate organ function
- Must have positive EBV titres
- Women of child-bearing potential must have a negative pregnancy test. Patients of both genders must be willing to practice birth control during treatment and for 6 months post completion of IL-2 treatment.
- Exclusion Criteria:
- Requiring systemic steroid therapy
- HIV positive
- With active hepatitis B or hepatitis C, syphilis, or HTLV
- Must not have any active systemic infections, coagulation disorders or other active major medical illnesses of the cardiovascular, respiratory or immune system, uncontrolled psychiatric disorders, or other conditions that may affect following study procedures.
- Have no active underlying cardiac illnesses defined by positive stress test, LVEF\<40% or ongoing life-threatening arrhythmias
- Abnormal lung function test
Exclusion
Key Trial Info
Start Date :
June 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2018
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01883323
Start Date
June 1 2013
End Date
April 1 2018
Last Update
November 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9